Dermatan sulfate: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject |
consistent citation formatting |
||
(47 intermediate revisions by 28 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Glycosaminoglycan found in animals}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
⚫ | |||
| Watchedfields = changed |
|||
⚫ | |||
| image = Dermatan sulfate.PNG |
| image = Dermatan sulfate.PNG |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| Drugs.com = {{drugs.com|international|dermatan-sulfate}} |
| Drugs.com = {{drugs.com|international|dermatan-sulfate}} |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
||
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| CAS_number = 24967-94-0 |
| CAS_number = 24967-94-0 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = J3OC7JVS54 |
|||
| ATC_prefix = B01 |
| ATC_prefix = B01 |
||
| ATC_suffix = AX04 |
| ATC_suffix = AX04 |
||
| ChemSpiderID_Ref = {{chemspidercite| |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
⚫ | |||
| C=14 | H=21 | N=1 | O=15 | S=1 |
|||
⚫ | |||
| molecular_weight = |
|||
| smiles = [O-]C(=O)[C@@H]2O[C@@H](O[C@H]1[C@@H](OS([O-])(=O)=O)[C@H](O[C@@H](O)[C@@H]1NC(=O)C)CO)[C@H](O)[C@@H](O)[C@@H]2O |
|||
|drug_name=|alt=|caption=|type=|MedlinePlus=|legal_status=|licence_EU=|pregnancy_category=|licence_US=|DrugBank=}} |
|||
| InChI = 1/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/p-2/t4-,5-,6+,7+,8-,9+,10-,11-,13-,14-/m1/s1 |
|||
| InChIKey = AVJBPWGFOQAPRH-SRMSFAINBD |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChI = 1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/p-2/t4-,5-,6+,7+,8-,9+,10-,11-,13-,14-/m1/s1 |
|||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChIKey = AVJBPWGFOQAPRH-FWMKGIEWSA-L |
|||
}} |
|||
'''Dermatan sulfate''' is a [[glycosaminoglycan]] (formerly called a mucopolysaccharide) found mostly in [[skin]], but also in [[blood vessels]], [[heart valves]], [[tendons]], and [[lungs]]. |
'''Dermatan sulfate''' is a [[glycosaminoglycan]] (formerly called a mucopolysaccharide) found mostly in [[skin]], but also in [[blood vessels]], [[heart valves]], [[tendons]], and [[lungs]]. |
||
It is also referred to as [[chondroitin sulfate|chondroitin sulfate B]], |
It is also referred to as [[chondroitin sulfate|chondroitin sulfate B]],<ref name = "Trowbridge_2002">{{cite journal | vauthors = Trowbridge JM, Gallo RL | title = Dermatan sulfate: new functions from an old glycosaminoglycan | journal = Glycobiology | volume = 12 | issue = 9 | pages = 117R–125R | date = September 2002 | pmid = 12213784 | doi = 10.1093/glycob/cwf066 | doi-access = free }}</ref> although it is no longer classified as a form of chondroitin sulfate by most sources. The formula is C<sub>14</sub>H<sub>21</sub>NO<sub>15</sub>S. This carbohydrate is composed of linear polymers of disaccharide units that contain, [[N-acetyl galactosamine]] (GalNAc) and [[iduronic acid]] (IdoA). These repeating units are sulfated at a variety of positions.<ref>{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/Dermatan-sulfate|title = Dermatan sulfate}}</ref> Dermatan sulfate is a component of the compound [[sulodexide]].<ref name="Lasierra-Cirujeda 2010">{{cite journal | vauthors = Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M | title = Use of sulodexide in patients with peripheral vascular disease | journal = Journal of Blood Medicine | volume = 1 | pages = 105–115 | date = 2010 | pmid = 22282689 | pmc = 3262318 | doi = 10.2147/JBM.S10558 | quote = Sulodexide is a highly purified glycosaminoglycan (GAG) obtained from porcine digestive mucosa and is composed of a mixture of 80% heparan sulfate (an electrophoretically fast moving fraction with a low molecular weight of 7000 Da and affinity for antithrombin III) and 20% dermatan sulfate with a high molecular weight (25,000 Da) and affinity for the heparin II cofactor. | doi-access = free }}</ref> |
||
==Function== |
== Function == |
||
Dermatan sulfate may have roles in [[coagulation]], [[cardiovascular disease]], [[carcinogenesis]], [[infection]], [[wound repair]], and [[fibrosis]]. |
Dermatan sulfate may have roles in [[coagulation]], [[cardiovascular disease]], [[carcinogenesis]], [[infection]], [[wound repair]], maintaining the shape of galactosamine 4-sulfate, skin, and [[fibrosis]].<ref name = "Trowbridge_2002" /> |
||
==Pathology== |
==Pathology== |
||
Dermatan sulfate accumulates abnormally in several of the [[mucopolysaccharidosis]] disorders. |
Dermatan sulfate accumulates abnormally in several of the [[mucopolysaccharidosis]] disorders. |
||
An excess of |
An excess of dermatan sulfate in the [[mitral valve]] is characteristic of myxomatous degeneration of the leaflets leading to redundancy of valve [[tissue (biology)|tissue]] and ultimately, [[mitral valve prolapse]] (into the [[left atrium]]) and insufficiency. This chronic prolapse occurs mainly in women over the age of 60, and can predispose the [[patient]] to [[mitral annular calcification]]. [[Mitral insufficiency|Mitral valve insufficiency]] can lead to eccentric (volume dependent or dilated) [[Hypertrophic cardiomyopathy|hypertrophy]] and eventually [[left heart]] failure if untreated. |
||
==See also== |
== See also == |
||
* [[ |
* [[Iduronic acid]] |
||
== |
== References == |
||
⚫ | |||
== External links == |
|||
* {{MeshName|Dermatan+sulfate}} |
* {{MeshName|Dermatan+sulfate}} |
||
==References== |
|||
⚫ | |||
{{Antithrombotics}} |
{{Antithrombotics}} |
||
Line 55: | Line 52: | ||
[[Category:Glycosaminoglycans]] |
[[Category:Glycosaminoglycans]] |
||
[[Category:Sulfate esters]] |
|||
{{biochem-stub}} |
|||
{{pharma-stub}} |
|||
[[ca:Sulfat dermatà]] |
|||
[[el:Θειική δερματάνη]] |
|||
[[fa:درماتان سولفات]] |
|||
[[it:Dermatan solfato]] |
|||
[[ja:デルマタン硫酸]] |
|||
[[pt:Sulfato de dermatan]] |
|||
[[fi:Dermataanisulfaatti]] |